Wintermute Biomedical are excited our ZosterEase Phase Ib clinical trial’s patient recruitment is now fulfilled.
Preliminary safety results expected shortly. Read more here.
Preliminary safety results expected shortly. Read more here.
A recent report from PainAustralia shines light on the long-term pain impact for up to 30% of Australian shingles sufferers.
Shingles isn't just a rash! Sadly, for many it can be ongoing pain for months and years.
According to PainAustralia new 2025 'Shingles: It's Not Just A Rash' report, nearly 120,000 Australians are diagnosed with shingles every year. One in three people will experience it in their lifetime, and for many, the pain doesn't stop when the rash fades. Up to 30% go on to develop post-herpetic neuralgia (PHN), a form of nerve pain that can persist for months or even years. Currently available treatments are limited, with few effective options for pain relief or antiviral therapy. The findings of this report reinforces the urgency of what we’re working on at Wintermute Biomedical. Our solution, Solexan™, is a novel topical therapy designed to offer both antiviral action and pain relief!
For more information, you can find the full report from Pain Australia here: